BACKGROUND. Datasets linked to molecular phenotypes are desperately needed to provide academia and industry the real-world evidence needed for discovery, validation and implementation of new biomarkers for improved cancer outcomes.
The Cancer Research UK Beatson Institute in Glasgow is one of the world leading centres for cancer research. The Institute provides an outstanding research environment, underpinned by state-of-the-art core services and advanced technologies with special emphasis on imaging, metabolomics and in vivo models of cancer.
Alzhemier’s Disease (AD) is the most common form of dementia in the UK. There is no one cause, it is a multi-factoral disease. Oxidative stress is believed to be one of the factors or pathologies which contributes to AD.
In humans, the cysteine-containing tripeptide glutathione (GSH) is an essential thiol cofactor that maintains an intracellular reducing environment to protect against oxidative stress reactive oxygen species, which cause lipid, protein & DNA damage.
Synapses are the microprocessors of the mind that encode and store memories. In Alzheimer’s disease (AD), synapses are damaged by the constituents of abnormal beta-amyloid plaques that accumulate in the brain.
Mucopolysaccharidoses (MPS) are inherited metabolic disorders caused by the deficiency of specific lysosomal enzymes required for the catabolism of glycosaminoglycans (GAGs) where each MPS type lacks a specific enzyme resulting in the build-up of GAGs in all cells of the body.